Monitor the LYMPHIR revenue trajectory over the next 1-2 quarters for signs of sustainable growth; the company's limited cash runway (through Nov 2026) and reliance on additional financing create near-term dilution risk. The subsequent financing at Citius Oncology is positive but does not offset the core cash burn.
Price Chart
Executive Summary
Citius Pharmaceuticals reported Q2 fiscal 2026 revenue of $1.7M (vs $0 a year ago) from LYMPHIR sales, but net loss widened to $21.2M ($0.95/sh) from $10.9M ($1.27/sh) in the prior-year quarter, driven by a $19.7M one-time CMO cancellation charge. Cash dropped to $4.6M, and the company raised $5M in a direct offering in April 2026, while Citius Oncology secured up to $36.5M in debt/equity. Despite commercial progress, the growing losses and cash burn signal ongoing capital needs and dilution risk.
Key Financial Metrics
Key Facts
- Q2 FY2026 net product revenue of $1.7M, down from $3.9M in Q1 (initial launch stocking orders)
- Net loss applicable to common stockholders of $21.2M vs $10.9M in Q2 2025
- G&A expenses surged to $26.4M from $4.8M, including a $19.7M one-time CMO contract cancellation charge
- Cash and cash equivalents fell to $4.6M at March 31, 2026, from $7.7M at December 31, 2025
- Subsequent to quarter end: $5M registered direct offering at Citius Pharma; Citius Oncology secured up to $36.5M debt/equity
- Company expects sufficient funds to continue operations only through November 2026
Financial Impact
Net loss doubled YoY to $21.2M; cash burn of ~$14.3M in operating cash flow for H1 FY2026
Risk Factors
- Dilution from recent and potential future equity offerings
- Cash runway only through November 2026; going-concern risk if revenue does not ramp
- Commercial execution risk for LYMPHIR; QoQ revenue decline from launch quarter
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-057876 |
| Document: ea0291037-8k_citius.htm | 0001213900-26-057876 |
| Document: 0001213900-26-057876-index-headers.html | 0001213900-26-057876 |
| Document: 0001213900-26-057876-index.html | 0001213900-26-057876 |
| Document: 0001213900-26-057876.txt | 0001213900-26-057876 |
| 8-K Data (Synthetic) | 0001213900-26-057876 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | 8-K | $0.4582 | awaiting T+60 | — | $0.4490 (−2.01%) |
Aug 5, 2026 11w ago | 8-K | $0.7809 | awaiting T+60 | — | $0.4490 (−42.50%) |
Jun 3, 2026 20w ago | EFFECT | $0.5800 $0.6290 | ▼ −8.45% | ▼ −5.95% | $0.4490 (+22.59%) |
Jun 1, 2026 21w ago | 8-K | $0.6030 $0.5771 | ▼ −4.30% | ▼ −5.41% | $0.4490 (−25.54%) |
May 22, 2026 22w ago | S-3 | $0.6970 $0.6375 | ▲ +8.54% | ▲ +11.26% | $0.4490 (+35.58%) |
May 15, 2026 23w ago | 8-K | $0.5270 $0.7650 | ▼ −45.16% | ▼ −40.31% | $0.4490 (+14.80%) |
Apr 24, 2026 26w ago | 8-K | $0.6910 $0.5623 | ▲ +18.63% | ▲ +23.40% | $0.4490 (+35.02%) |
Apr 24, 2026 26w ago | 424B5 | $0.7700 $0.5455 | ▲ +29.16% | ▲ +34.24% | $0.4490 (+41.69%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers